Obstetrical ||| S:0 E:11 ||| NNP
,  ||| S:11 E:13 ||| ,
fetal  ||| S:13 E:19 ||| JJ
and  ||| S:19 E:23 ||| CC
postnatal  ||| S:23 E:33 ||| JJ
effects  ||| S:33 E:41 ||| NNS
of  ||| S:41 E:44 ||| IN
gestational  ||| S:44 E:56 ||| JJ
antiblastic  ||| S:56 E:68 ||| JJ
chemotherapy ||| S:68 E:80 ||| NN
:  ||| S:80 E:82 ||| :
how  ||| S:82 E:86 ||| WRB
to  ||| S:86 E:89 ||| TO
counsel  ||| S:89 E:97 ||| NN
cancer  ||| S:97 E:104 ||| NN
patients  ||| S:104 E:113 ||| NNS
At  ||| S:113 E:116 ||| IN
least  ||| S:116 E:122 ||| JJS
one  ||| S:122 E:126 ||| CD
in  ||| S:126 E:129 ||| IN
a  ||| S:129 E:131 ||| DT
thousand  ||| S:131 E:140 ||| CD
pregnancies  ||| S:140 E:152 ||| NN
is  ||| S:152 E:155 ||| VBZ
complicated  ||| S:155 E:167 ||| VBN
by  ||| S:167 E:170 ||| IN
cancer  ||| S:170 E:177 ||| NN
and ||| S:177 E:180 ||| CC
,  ||| S:180 E:182 ||| ,
as  ||| S:182 E:185 ||| IN
the  ||| S:185 E:189 ||| DT
maternal  ||| S:189 E:198 ||| JJ
age  ||| S:198 E:202 ||| NN
at  ||| S:202 E:205 ||| IN
pregnancy  ||| S:205 E:215 ||| NN
increases ||| S:215 E:224 ||| NNS
,  ||| S:224 E:226 ||| ,
numbers  ||| S:226 E:234 ||| NNS
are  ||| S:234 E:238 ||| VBP
growing ||| S:238 E:245 ||| VBG
.  ||| S:245 E:247 ||| .
If  ||| S:247 E:250 ||| IN
chemotherapy  ||| S:250 E:263 ||| JJ
cannot  ||| S:263 E:270 ||| NNS
be  ||| S:270 E:273 ||| VB
postponed ||| S:273 E:282 ||| VBN
,  ||| S:282 E:284 ||| ,
both  ||| S:284 E:289 ||| DT
doctors  ||| S:289 E:297 ||| NNS
and  ||| S:297 E:301 ||| CC
patients  ||| S:301 E:310 ||| NNS
face  ||| S:310 E:315 ||| VBP
complex  ||| S:315 E:323 ||| JJ
medical  ||| S:323 E:331 ||| JJ
and  ||| S:331 E:335 ||| CC
ethical  ||| S:335 E:343 ||| JJ
issues ||| S:343 E:349 ||| NNS
.  ||| S:349 E:351 ||| .
There  ||| S:351 E:357 ||| EX
is  ||| S:357 E:360 ||| VBZ
a  ||| S:360 E:362 ||| DT
conflict  ||| S:362 E:371 ||| NN
between  ||| S:371 E:379 ||| IN
optimal  ||| S:379 E:387 ||| JJ
maternal  ||| S:387 E:396 ||| JJ
therapy  ||| S:396 E:404 ||| NN
and  ||| S:404 E:408 ||| CC
fetal  ||| S:408 E:414 ||| JJ
wellbeing ||| S:414 E:423 ||| NN
.  ||| S:423 E:425 ||| .
Treatment  ||| S:425 E:435 ||| NN
during  ||| S:435 E:442 ||| IN
the  ||| S:442 E:446 ||| DT
first  ||| S:446 E:452 ||| JJ
trimester  ||| S:452 E:462 ||| NN
increases  ||| S:462 E:472 ||| VBZ
the  ||| S:472 E:476 ||| DT
risk  ||| S:476 E:481 ||| NN
of  ||| S:481 E:484 ||| IN
congenital  ||| S:484 E:495 ||| JJ
malformations ||| S:495 E:508 ||| NN
,  ||| S:508 E:510 ||| ,
spontaneous  ||| S:510 E:522 ||| JJ
abortions  ||| S:522 E:532 ||| NNS
and  ||| S:532 E:536 ||| CC
fetal  ||| S:536 E:542 ||| JJ
death ||| S:542 E:547 ||| NN
.  ||| S:547 E:549 ||| .
Second  ||| S:549 E:556 ||| JJ
and  ||| S:556 E:560 ||| CC
third  ||| S:560 E:566 ||| JJ
trimester  ||| S:566 E:576 ||| JJ
exposure  ||| S:576 E:585 ||| NN
is  ||| S:585 E:588 ||| VBZ
less  ||| S:588 E:593 ||| RBR
risky ||| S:593 E:598 ||| JJ
,  ||| S:598 E:600 ||| ,
but  ||| S:600 E:604 ||| CC
it  ||| S:604 E:607 ||| PRP
can  ||| S:607 E:611 ||| MD
cause  ||| S:611 E:617 ||| VB
intrauterine  ||| S:617 E:630 ||| JJ
growth  ||| S:630 E:637 ||| NN
retardation  ||| S:637 E:649 ||| NN
and  ||| S:649 E:653 ||| CC
low  ||| S:653 E:657 ||| JJ
birth  ||| S:657 E:663 ||| NN
weight ||| S:663 E:669 ||| NN
.  ||| S:669 E:671 ||| .
Other  ||| S:671 E:677 ||| JJ
effects  ||| S:677 E:685 ||| NNS
on  ||| S:685 E:688 ||| IN
pregnancy  ||| S:688 E:698 ||| NN
after  ||| S:698 E:704 ||| IN
the  ||| S:704 E:708 ||| DT
first  ||| S:708 E:714 ||| JJ
trimester  ||| S:714 E:724 ||| NNS
include  ||| S:724 E:732 ||| VBP
premature  ||| S:732 E:742 ||| JJ
birth ||| S:742 E:747 ||| NN
,  ||| S:747 E:749 ||| ,
stillbirth ||| S:749 E:759 ||| NN
,  ||| S:759 E:761 ||| ,
impaired  ||| S:761 E:770 ||| VBN
functional  ||| S:770 E:781 ||| JJ
development ||| S:781 E:792 ||| NN
,  ||| S:792 E:794 ||| ,
myocardial  ||| S:794 E:805 ||| JJ
toxicity  ||| S:805 E:814 ||| NN
and  ||| S:814 E:818 ||| CC
myelosuppression ||| S:818 E:834 ||| NN
.  ||| S:834 E:836 ||| .
Counseling  ||| S:836 E:847 ||| NN
and  ||| S:847 E:851 ||| CC
management  ||| S:851 E:862 ||| NN
of  ||| S:862 E:865 ||| IN
these  ||| S:865 E:871 ||| DT
cases  ||| S:871 E:877 ||| NNS
are  ||| S:877 E:881 ||| VBP
difficult ||| S:881 E:890 ||| JJ
,  ||| S:890 E:892 ||| ,
because  ||| S:892 E:900 ||| IN
literature  ||| S:900 E:911 ||| NN
is  ||| S:911 E:914 ||| VBZ
mostly  ||| S:914 E:921 ||| RB
represented  ||| S:921 E:933 ||| VBN
by  ||| S:933 E:936 ||| IN
case  ||| S:936 E:941 ||| NN
reports  ||| S:941 E:949 ||| NNS
or  ||| S:949 E:952 ||| CC
retrospective  ||| S:952 E:966 ||| JJ
series  ||| S:966 E:973 ||| NN
while  ||| S:973 E:979 ||| IN
randomized  ||| S:979 E:990 ||| JJ
prospective  ||| S:990 E:1002 ||| JJ
studies  ||| S:1002 E:1010 ||| NNS
or  ||| S:1010 E:1013 ||| CC
guidelines  ||| S:1013 E:1024 ||| NNS
are  ||| S:1024 E:1028 ||| VBP
lacking ||| S:1028 E:1035 ||| VBG
.  ||| S:1035 E:1037 ||| .
Moreover ||| S:1037 E:1045 ||| RB
,  ||| S:1045 E:1047 ||| ,
personal  ||| S:1047 E:1056 ||| JJ
experience  ||| S:1056 E:1067 ||| NN
is  ||| S:1067 E:1070 ||| VBZ
often  ||| S:1070 E:1076 ||| RB
scanty  ||| S:1076 E:1083 ||| JJ
due  ||| S:1083 E:1087 ||| JJ
to  ||| S:1087 E:1090 ||| TO
the  ||| S:1090 E:1094 ||| DT
rarity  ||| S:1094 E:1101 ||| NN
of  ||| S:1101 E:1104 ||| IN
the  ||| S:1104 E:1108 ||| DT
condition ||| S:1108 E:1117 ||| NN
.  ||| S:1117 E:1119 ||| .
This  ||| S:1119 E:1124 ||| DT
article  ||| S:1124 E:1132 ||| NN
reviews  ||| S:1132 E:1140 ||| VBZ
the  ||| S:1140 E:1144 ||| DT
available  ||| S:1144 E:1154 ||| JJ
data  ||| S:1154 E:1159 ||| NNS
regarding  ||| S:1159 E:1169 ||| VBG
the  ||| S:1169 E:1173 ||| DT
different  ||| S:1173 E:1183 ||| JJ
aspects  ||| S:1183 E:1191 ||| NNS
of  ||| S:1191 E:1194 ||| IN
systemic  ||| S:1194 E:1203 ||| JJ
treatment  ||| S:1203 E:1213 ||| NN
of  ||| S:1213 E:1216 ||| IN
cancer  ||| S:1216 E:1223 ||| NN
during  ||| S:1223 E:1230 ||| IN
pregnancy  ||| S:1230 E:1240 ||| NN
to  ||| S:1240 E:1243 ||| TO
help  ||| S:1243 E:1248 ||| VB
oncologist  ||| S:1248 E:1259 ||| NNS
and  ||| S:1259 E:1263 ||| CC
obstetricians  ||| S:1263 E:1277 ||| NN
in  ||| S:1277 E:1280 ||| IN
counseling  ||| S:1280 E:1291 ||| VBG
their  ||| S:1291 E:1297 ||| PRP$
patients  ||| S:1297 E:1306 ||| NNS
and  ||| S:1306 E:1310 ||| CC
treat  ||| S:1310 E:1316 ||| VB
them  ||| S:1316 E:1321 ||| PRP
accordingly ||| S:1321 E:1332 ||| RB
.  ||| S:1332 E:1334 ||| .
